|
2M2D
Human programmed cell death 1 receptor
Deposited 2012-12-18
|
Different construct
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
34–150(117 aa)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.4;298 K;Ionic strength (raw mmCIF value) 0.125;Pressure ambient
NMR sample composition
0.5 mM [U-15N] protein, 25 mM potassium phosphate, 100 mM sodium chloride, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition
0.5 mM [U-13C; U-15N] protein, 25 mM potassium phosphate, 100 mM sodium chloride, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition
0.5 mM protein, 25 mM potassium phosphate, 100 mM sodium chloride, 100% D2O | 100% D2O
|
Resolution not provided
|
|
3RRQ
Crystal structure of the extracellular domain of human PD-1
Deposited 2011-04-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
32–160(129 aa)
Fragment:Residues 32-160
|
Mutation:A132L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;298 K;3.5M Sodium formate, 0.1M Bis-Tris, pH 7.5, Vapor diffusion, Sitting drop, temperature 298K, VAPOR DIFFUSION, SITTING DROP
|
Resolution 2.10 Å
R-free 0.249
|
|
4ZQK
Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1.
Deposited 2015-05-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
33–150(118 aa)
Fragment:UNP Residues 33-150
|
Mutation:C93S
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;295 K;0.1 M BIS-Tris pH 5.5, 1.84 M ammonium sulfate
|
Resolution 2.45 Å
R-free 0.253
|
|
5B8C
High resolution structure of the human PD-1 in complex with pembrolizumab Fv
Deposited 2016-06-14
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain C
32–160(129 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;20 % PEG 3350, 0.2 M KNO3
|
Resolution 2.15 Å
R-free 0.226
|
|
5B8C
High resolution structure of the human PD-1 in complex with pembrolizumab Fv
Deposited 2016-06-14
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain F
32–160(129 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;20 % PEG 3350, 0.2 M KNO3
|
Resolution 2.15 Å
R-free 0.226
|
|
5B8C
High resolution structure of the human PD-1 in complex with pembrolizumab Fv
Deposited 2016-06-14
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain I
32–160(129 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;20 % PEG 3350, 0.2 M KNO3
|
Resolution 2.15 Å
R-free 0.226
|
|
5B8C
High resolution structure of the human PD-1 in complex with pembrolizumab Fv
Deposited 2016-06-14
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain L
32–160(129 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;20 % PEG 3350, 0.2 M KNO3
|
Resolution 2.15 Å
R-free 0.226
|
|
5GGR
PD-1 in complex with nivolumab Fab
Deposited 2016-06-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain Y
26–150(125 aa)
Fragment:UNP residues 26-150
|
Mutation:C93S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM MES, pH 6.5, 12% PEG500 MME, 6% PEG20,000, 50 mM ammonium acetate
|
Resolution 3.30 Å
R-free 0.268
|
|
5GGR
PD-1 in complex with nivolumab Fab
Deposited 2016-06-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain Z
26–150(125 aa)
Fragment:UNP residues 26-150
|
Mutation:C93S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM MES, pH 6.5, 12% PEG500 MME, 6% PEG20,000, 50 mM ammonium acetate
|
Resolution 3.30 Å
R-free 0.268
|
|
5GGS
PD-1 in complex with pembrolizumab Fab
Deposited 2016-06-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain Z
26–148(123 aa)
Fragment:UNP residues 26-148
|
Mutation:C93S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM MES, pH 6.5, 12% PEG500 MME, 6% PEG20,000, 50 mM ammonium acetate
|
Resolution 2.00 Å
R-free 0.228
|
|
5GGS
PD-1 in complex with pembrolizumab Fab
Deposited 2016-06-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain Y
26–148(123 aa)
Fragment:UNP residues 26-148
|
Mutation:C93S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM MES, pH 6.5, 12% PEG500 MME, 6% PEG20,000, 50 mM ammonium acetate
|
Resolution 2.00 Å
R-free 0.228
|
|
5IUS
Crystal structure of human PD-L1 in complex with high affinity PD-1 mutant
Deposited 2016-03-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–146(121 aa)
|
Mutation:V64H, N66V, Y68H, M70E, N74G, K78T, C93A, L122V, A125V, A132I
|
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.4;293 K;0.1 M bis-TRIS pH 6.4, 17% PEG MME 5000, 2 mM LiCl
|
Resolution 2.89 Å
R-free 0.260
|
|
5IUS
Crystal structure of human PD-L1 in complex with high affinity PD-1 mutant
Deposited 2016-03-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
26–146(121 aa)
|
Mutation:V64H, N66V, Y68H, M70E, N74G, K78T, C93A, L122V, A125V, A132I
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.4;293 K;0.1 M bis-TRIS pH 6.4, 17% PEG MME 5000, 2 mM LiCl
|
Resolution 2.89 Å
R-free 0.260
|
|
5JXE
Human PD-1 ectodomain complexed with Pembrolizumab Fab
Deposited 2016-05-13
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
33–146(114 aa)
Fragment:UNP RESIDUES 34-146
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;0.1 M sodium citrate pH 5.6, 19 mM n-Decyl-N,N-dimethylglycine, 20% isopropanol and 20% PEG 4000
|
Resolution 2.90 Å
R-free 0.286
|
|
5JXE
Human PD-1 ectodomain complexed with Pembrolizumab Fab
Deposited 2016-05-13
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
33–146(114 aa)
Fragment:UNP RESIDUES 34-146
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;0.1 M sodium citrate pH 5.6, 19 mM n-Decyl-N,N-dimethylglycine, 20% isopropanol and 20% PEG 4000
|
Resolution 2.90 Å
R-free 0.286
|
|
5WT9
Complex structure of PD-1 and nivolumab-Fab
Deposited 2016-12-10
|
Different construct
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain G
1–167(167 aa)
Fragment:UNP RESIDUES 1-167
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;277 K;0.2M Ammonium acetate, 0.1 M BIS-TRIS pH5.5, 25% w/v Polyethylene glycol 3350
|
Resolution 2.40 Å
R-free 0.228
|
|
6HIG
hPD-1/NBO1a Fab complex
Deposited 2018-08-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
33–150(118 aa)
|
Mutation:C93S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.2 M NH4I
20 % PEG 3.35 K
|
Resolution 2.20 Å
R-free 0.270
|
|
6J14
Complex structure of GY-14 and PD-1
Deposited 2018-12-27
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain G
33–147(115 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 6.5;277 K;0.06 M MgCl2, CaCl2, 0.1 M imidazole-MES (pH 6.5), 18% v/v ethylene glycol and polyethylene glycol 8000
|
Resolution 1.40 Å
R-free 0.215
|
|
6J15
Complex structure of GY-5 Fab and PD-1
Deposited 2018-12-27
|
Different construct
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain C
32–147(116 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;277 K;0.1 M citrate (pH 5.0), 20% w/v polyethylene glycol 6000, 0.2 M ammonium acetate
|
Resolution 2.60 Å
R-free 0.277
|
|
6J15
Complex structure of GY-5 Fab and PD-1
Deposited 2018-12-27
|
Different construct
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain D
32–147(116 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;277 K;0.1 M citrate (pH 5.0), 20% w/v polyethylene glycol 6000, 0.2 M ammonium acetate
|
Resolution 2.60 Å
R-free 0.277
|
|
6JBT
Complex structure of toripalimab-Fab and PD-1
Deposited 2019-01-26
|
Different construct
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain F
21–170(150 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;277 K;0.09 M Halogens consisting of NaF, NaBr and NaI additives, 0.1 M Tris-Base (pH8.5), 37.5% (v/v) MPD-P1K-P3350 consisting of MPD (racemic), PEG 1K and PEG 3350
|
Resolution 2.47 Å
R-free 0.252
|
|
6JJP
Crystal structure of Fab of a PD-1 monoclonal antibody MW11-h317 in complex with PD-1
Deposited 2019-02-26
|
Different construct
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain C
21–167(147 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;289 K;0.1 M Bis-Tris (pH 6.5) and 28% polyethylene glycol monomethyl ether 2000
|
Resolution 2.90 Å
R-free 0.247
|
|
6JJP
Crystal structure of Fab of a PD-1 monoclonal antibody MW11-h317 in complex with PD-1
Deposited 2019-02-26
|
Different construct
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain F
21–167(147 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;289 K;0.1 M Bis-Tris (pH 6.5) and 28% polyethylene glycol monomethyl ether 2000
|
Resolution 2.90 Å
R-free 0.247
|
|
6K0Y
Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
Deposited 2019-05-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain C
25–167(143 aa)
|
Mutation:C93S
|
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;293 K;0.2M NaCl , 0.1M Tris pH 8, 14% PEG 4K
|
Resolution 1.70 Å
R-free 0.214
|
|
6UMT
High-affinity human PD-1 PD-L2 complex
Deposited 2019-10-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
33–150(118 aa)
Fragment:UNP residues 33-150
|
Mutation:N74G, T76P, A132V
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;200 mM magnesium acetate, 10% w/v PEG8000
|
Resolution 1.99 Å
R-free 0.226
|
|
6UMU
Human apo PD-1 triple mutant
Deposited 2019-10-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
33–150(118 aa)
Fragment:UNP residues 33-150
|
Mutation:N74G, T76P, A132V
|
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM sodium chloride, 100 mM Tris-HCl, pH 8.0, 27% w/v PEG5000 MME
|
Resolution 1.18 Å
R-free 0.164
|
|
6UMV
Human apo PD-1 double mutant
Deposited 2019-10-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
33–150(118 aa)
Fragment:UNP residues 33-150
|
Mutation:T76P, A132V
|
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM sodium chloride, 100 mM Tris-HCl, pH 8.0, 36% w/v PEG3350
|
Resolution 1.42 Å
R-free 0.189
|
|
6XKR
Structure of Sasanlimab Fab in complex with PD-1
Deposited 2020-06-27
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain P
32–160(129 aa)
|
Not recorded
|
GOL GLYCEROL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4;298 K;0.5M LiCl, 0.1M Citric Acid, pH 4, 22% w/v PEG 6000, 0.5% w/v ODG
|
Resolution 2.59 Å
R-free 0.271
|
|
7BXA
Crystal structure of PD-1 in complex with tislelizumab Fab
Deposited 2020-04-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
29–150(122 aa)
|
Mutation:C93S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.2 M ammonium sulfate, 30% w/v polyethylene glycol 4000
|
Resolution 3.32 Å
R-free 0.299
|
|
7BXA
Crystal structure of PD-1 in complex with tislelizumab Fab
Deposited 2020-04-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain P
29–150(122 aa)
|
Mutation:C93S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.2 M ammonium sulfate, 30% w/v polyethylene glycol 4000
|
Resolution 3.32 Å
R-free 0.299
|
|
7CGW
Complex structure of PD-1 and tislelizumab Fab
Deposited 2020-07-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain C
25–169(145 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4;293 K;0.1M Citric acid, pH4.0, 1M LiCl and 20% PEG6000
|
Resolution 3.20 Å
R-free 0.254
|
|
7CGW
Complex structure of PD-1 and tislelizumab Fab
Deposited 2020-07-02
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain P
25–169(145 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4;293 K;0.1M Citric acid, pH4.0, 1M LiCl and 20% PEG6000
|
Resolution 3.20 Å
R-free 0.254
|
|
7CU5
N-Glycosylation of PD-1 and glycosylation dependent binding of PD-1 specific monoclonal antibody camrelizumab
Deposited 2020-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain E
30–147(118 aa)
Chain Q
30–147(118 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;0.1M cadmium chloride, 0.1M Na acetate, pH4.6, 30 %(v/v) PEG 400 a month later.
|
Resolution 2.81 Å
R-free 0.252
|
|
7E9B
Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy
Deposited 2021-03-04
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain C
32–146(115 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;0.1 M Tris pH 7.5 containing 23% (w/v) PEG 4000
|
Resolution 1.78 Å
R-free 0.210
|
|
7VUX
Complex structure of PD1 and 609A-Fab
Deposited 2021-11-04
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
32–160(129 aa)
|
Not recorded
|
THR THREONINE × 1
GOL GLYCEROL × 7
EDO 1,2-ETHANEDIOL × 7
MG MAGNESIUM ION × 2
PEG DI(HYDROXYETHYL)ETHER × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291.15 K;0.2 M Ammonium formate, pH 6.6, 20% w/v PEG 3350
|
Resolution 1.64 Å
R-free 0.202
|
|
7WSL
PD-1 in complex with Dostarlimab
Deposited 2022-01-30
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain D
29–150(122 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.2M trimethylamine N-oxide dihydrate, 0.1M Tris pH 8.5, 20% w/v PEG 3350
|
Resolution 1.53 Å
R-free 0.178
|
|
7WVM
The complex structure of PD-1 and cemiplimab
Deposited 2022-02-10
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain E
31–147(117 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;0.1 M Sodium acetate, pH 5.0, 5% w/v PGA (Na+ form, LM), 20% w/v PEG 2000 MME
|
Resolution 3.40 Å
R-free 0.287
|
|
7WVM
The complex structure of PD-1 and cemiplimab
Deposited 2022-02-10
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain F
31–147(117 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;0.1 M Sodium acetate, pH 5.0, 5% w/v PGA (Na+ form, LM), 20% w/v PEG 2000 MME
|
Resolution 3.40 Å
R-free 0.287
|
|
8EQ6
PD1 signaling receptor bound to FAB Complex
Deposited 2022-10-07
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
25–148(124 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;20.5% PEG 3350, 0.4M
MgCl2, 0.1M Bis-Tris pH 5.5
|
Resolution 1.65 Å
R-free 0.257
|
|
8GY5
High-resolution structure of the cemiplimab Fab in complex with PD-1
Deposited 2022-09-21
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain Q
26–150(125 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.2 M sodium formate, 20% PEG 3350
|
Resolution 1.98 Å
R-free 0.235
|
|
8GY5
High-resolution structure of the cemiplimab Fab in complex with PD-1
Deposited 2022-09-21
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain P
26–150(125 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.2 M sodium formate, 20% PEG 3350
|
Resolution 1.98 Å
R-free 0.235
|
|
8U31
Crystal structure of PD-1 in complex with a Fab
Deposited 2023-09-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
25–146(122 aa)
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;1% w/v Tryptone, 0.001 M Sodium azide,
0.05 M HEPES sodium pH 7.0, 20% w/v PEG 3,350
|
Resolution 2.73 Å
R-free 0.237
|
|
8U32
Crystal structure of PD-1 in complex with a Fab
Deposited 2023-09-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
25–146(122 aa)
|
Mutation:C93S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;20 %w/v PEG 3350, 0.2 M Na2 Malon, 0.1 M BIS-TRIS prop pH 8.5
|
Resolution 2.51 Å
R-free 0.230
|
|
8U32
Crystal structure of PD-1 in complex with a Fab
Deposited 2023-09-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain D
25–146(122 aa)
|
Mutation:C93S
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;20 %w/v PEG 3350, 0.2 M Na2 Malon, 0.1 M BIS-TRIS prop pH 8.5
|
Resolution 2.51 Å
R-free 0.230
|
|
9EHT
Crystal Structure of PD-1/retifanlimab complex
Deposited 2024-11-25
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain J
26–150(125 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;35.00 % (w/v) 2,4-methyl pentanediol, 200 mM Sodium chloride, and 100 mM Tris at pH 7.0
|
Resolution 1.54 Å
R-free 0.208
|
|
9EHT
Crystal Structure of PD-1/retifanlimab complex
Deposited 2024-11-25
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain F
26–150(125 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;35.00 % (w/v) 2,4-methyl pentanediol, 200 mM Sodium chloride, and 100 mM Tris at pH 7.0
|
Resolution 1.54 Å
R-free 0.208
|
|
9HK1
PD1 signaling receptor bound to FAB Complex
Deposited 2024-12-02
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
25–148(124 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;20.5% PEG 3350, 0.4M
MgCl2, 0.1M Bis-Tris pH 5.5
|
Resolution 2.03 Å
R-free 0.276
|
|
9HK1
PD1 signaling receptor bound to FAB Complex
Deposited 2024-12-02
|
Different construct
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
25–148(124 aa)
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;20.5% PEG 3350, 0.4M
MgCl2, 0.1M Bis-Tris pH 5.5
|
Resolution 2.03 Å
R-free 0.276
|
|
9Q8L
Crystal Structure of 21A08Ap1-Fab in Complex with Human PD-1 at 1.85 angstrom Resolution
Deposited 2025-02-25
|
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
24–170(147 aa)
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 4
DMS DIMETHYL SULFOXIDE × 1
PO4 PHOSPHATE ION × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;0.1 M Tris pH 8.5, 25% w/v PEG 3,350, 20% w/v MPD
|
Resolution 1.85 Å
R-free 0.216
|